Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices 37155

effective June 13, 2000, (section

306(d)(3)(B)(i) of the act).

Dated: June 6, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 00–14806 Filed 6–12–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00F–1332]

Ecolab, Inc.; Filing of Food Additive

Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Ecolab, Inc., has filed a petition

proposing that the food additive

regulations be amended to provide for

the safe use of a mixture of peroxyacetic

acid, octanoic acid, acetic acid,

hydrogen peroxide, peroxyoctanoic

acid, and 1-hydroxyethylidene-1,1-

diphosphonic acid as an antimicrobial

agent on red meat carcasses.

DATES: Submit written comments on the

petitioner’s environmental assessment

by July 13, 2000.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Robert L. Martin, Center for Food Safety

and Applied Nutrition (HFS–215), Food

and Drug Administration, 200 C St. SW.,

Washington, DC 20204–0001, 202–418–

3074.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),

notice is given that a food additive

petition (FAP 0A4720) has been filed by

Ecolab, Inc., Ecolab Center, 370

Wabasha St., St. Paul, MN 55102. The

petition proposes to amend the food

additive regulations in 21 CFR part 173

(21 CFR part 173) to provide for the safe

use of a mixture of peroxyacetic acid,

octanoic acid, acetic acid, hydrogen

peroxide, peroxyoctanoic acid, and 1-

hydroxyethylidene-1,1-diphosphonic

acid as an antimicrobial agent on red

meat carcasses.

The potential environmental impact

of this action is being reviewed. To

encourage public participation

consistent with regulations issued under

the National Environmental Policy Act

(40 CFR 1501.4(b)), the agency is

placing the environmental assessment

submitted with the petition that is the

subject of this notice on public display

at the Dockets Management Branch

(address above) for public review and

comment. Interested persons may

submit to the Dockets Management

Branch written comments by July 13,

2000. Two copies of any comments are

to be submitted, except that individuals

may submit one copy. Comments are to

be identified with the docket number

found in brackets in the heading of this

document. Received comments may be

seen in the Dockets Management Branch

between 9 a.m. and 4 p.m., Monday

through Friday. FDA will also place on

public display any amendments to, or

comments on, the petitioner’s

environmental assessment without

further announcement in the Federal

Register. If, based on its review, the

agency finds that an environmental

impact statement is not required and

this petition results in a regulation, the

notice of availability of the agency’s

finding of no significant impact and the

evidence supporting that finding will be

published with the regulation in the

Federal Register in accordance with 21

CFR 25.40(c).

Dated: May 30, 2000.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 00–14906 Filed 6–12–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Gastrointestinal Drugs Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Gastrointestinal

Drugs Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on June 26 and 27, 2000, 8:30 a.m.

to 5:30 p.m.

Location: Marriott Washington Center,

Ballrooms A through E, 9751

Washington Blvd., Gaithersburg, MD.

Contact Person: Thomas H. Perez,

Center for Drug Evaluation and Research

(HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–6758, email at PerezT@cder.fda.gov, or FDA

Advisory Committee Information Line,

1–800–741–8138 (301–443–0572 in the

Washington, DC area), code 12538.

Please call the Information Line for upto-date information on this meeting.

Agenda: On June 26, 2000, the

committee will discuss new drug

application (NDA) 21–200, ZelmacTM

(tegaserod), Novartis Pharmaceuticals

Corp., for the treatment of abdominal

pain and discomfort, bloating and

altered bowel function in patients with

irritable bowel syndrome who have

predominant symptoms of pain,

discomfort, and constipation. On June

27, 2000, the committee will discuss

risk management of post-marketing

adverse events associated with NDA 21–

107, LotronexTM (alosetron) Glaxo

Wellcome.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by June 19, 2000. Oral

presentations from the public will be

scheduled between approximately 1

p.m. and 2 p.m. Time allotted for each

presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before June 19, 2000, and submit

a brief statement of the general nature of

the evidence or arguments they wish to

present, the names and addresses of

proposed participants, and an

indication of the approximate time

requested to make their presentation.

FDA regrets that it was unable to

publish this notice 15 days prior to the

June 26 and 27, 2000, Gastrointestinal

Drugs Advisory Committee meeting.

Because the agency believes there is

some urgency to bring this issue to

public discussion and qualified

members of the Gastrointestinal Drugs

Advisory Committee were available at

this time, the Commissioner of Food

and Drugs concluded that it was in the

public interest to hold this meeting even

if there was not sufficient time for the

customary 15-day public notice.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

37156 Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices

Dated: June 5, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–14805 Filed 6–12–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

White House Initiative on Asian

Americans and Pacific Islanders

President’s Advisory Commission;

Notice of Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), announcement is

made of the following National

Advisory body scheduled to conduct a

public meeting by videoconference

during the month June 2000.

Name: President’s Advisory Commission

on Asian Americans and Pacific Islanders

(AAPIs).

Date and Time: June 26, 2000; 4:00 p.m.–

6:00 p.m. EST.

The meeting is open to the public.

The President’s Advisory Commission on

AAPIs will conduct a public meeting by

videoconference on June 26, from 4:00 p.m.

to 6:00 p.m. EST inclusive. The meeting is

open to the public; however, teleconference

lines are limited. Please call Mr. Tyson

Nakashima at (301) 443–2492, if you are

interested in participating in the call and to

obtain the dial-in number. Agenda items will

include, but will not be limited to: Approval

of May Commission Meeting minutes; reports

from subcommittees; administrative tasks;

deadlines; and the upcoming Town Hall and

Commission meetings.

The purpose of the Commission is to

advise the President on the issues facing

Asian Americans and Pacific Islanders

(AAPIs). The President’s Advisory

Commission on AAPIs will be seated through

June 7, 2001.

Requests to address the Commission

should be made in writing and should

include the name, address, telephone number

and business or professional affiliation of the

interested party. Individuals or groups

addressing similar issues are encouraged to

combine comments and present through a

single representative. The allocation of time

for remarks may be adjusted to accommodate

the level of expressed interest. Written

requests should be faxed to (301) 443–0259.

Anyone who has interest in joining any

portion of the meeting or who requires

additional information about the Commission

should contact: Mr. Tyson Nakashima, Office

of the White House Initiative on AAPIs,

Parklawn Building, Room 10–42, 5600

Fishers Lane, Rockville, MD, 20857,

Telephone (301) 443–2492. Anyone who

requires special assistance, such as sign

language interpretation or other reasonable

accommodations, should contact Mr.

Nakashima no later than June 19, 2000.

Dated: June 6, 2000.

Jane M. Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 00–14807 Filed 6–12–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of Inspector General; Program

Exclusions: May 2000

AGENCY: Office of Inspector General,

HHS.

ACTION: Notice of program exclusions.

During the month of May 2000, the

HHS Office of Inspector General

imposed exclusions in the cases set

forth below. When an exclusion is

imposed, no program payment is made

to anyone for any items or services

(other than an emergency item or

service not provided in a hospital

emergency room) furnished, ordered or

prescribed by an excluded party under

the Medicare, Medicaid, and all Federal

Health Care programs. In addition, no

program payment is made to any

business or facility, e.g., a hospital, that

submits bills for payment for items or

services provided by an excluded party.

Program beneficiaries remain free to

decide for themselves whether they will

continue to use the services of an

excluded party even though no program

payments will be made for items and

services provided by that excluded

party. The exclusions have national

effect and also apply to all Executive

Branch procurement and nonprocurement programs and activities.

Subject, city, state Effective

date

PROGRAM-RELATED CONVICTIONS

AKIN, CHARLES PHILIP, RAFTWOOD, TX ........................................................................................................................................... 06/20/00

AKOPYAN, GEVORK, LOS ANGELES, CA ........................................................................................................................................... 06/20/00

AKOPYAN, DANIEL, SAN DIEGO, CA ................................................................................................................................................... 06/20/00

BRIKER, RUSLAN, BROOKLYN, NY ..................................................................................................................................................... 06/20/00

BRITTAIN, RICHARD E JR, MANCHESTER, KY .................................................................................................................................. 06/20/00

CARABELLA, ROBERT, MANCHESTER, KY ........................................................................................................................................ 06/20/00

CHARLES, JOSEPH N, BROOKLYN, NY .............................................................................................................................................. 06/20/00

CHASSEREAU, DANIEL, EHRHARDT, SC ............................................................................................................................................ 06/20/00

COLLIER, JORDYCE A, MEDFORD, OR ............................................................................................................................................... 06/20/00

CORN, JOANN, DENVER, CO ............................................................................................................................................................... 02/14/99

CROW, DONNA M, SHENANDOAH, IA ................................................................................................................................................. 06/20/00

DINE, THEODORE SR, N SYRACUSE, NY ........................................................................................................................................... 06/20/00

DISHON, LORI A, BALTIMORE, MD ...................................................................................................................................................... 06/20/00

DOBY, KIMBERLY M, DENVER, CO ..................................................................................................................................................... 06/20/00

DOVALINA, ELSA, EAGLE PASS, TX .................................................................................................................................................... 06/20/00

DURAND, DEVIN, ENCINITAS, CA ........................................................................................................................................................ 06/20/00

DURANONA, RAFAEL ECHAVARRIA, MIAMI, FL ................................................................................................................................. 06/20/00

EKIZYAN, OGANES, LOS ANGELES, CA ............................................................................................................................................. 06/20/00

ELIZALDE, MARIA ROSA, MIAMI, FL .................................................................................................................................................... 06/20/00

EMBRIANO, PETER J, SOMERS, CT .................................................................................................................................................... 07/28/98

GARNER, WILMA J, BALTIMORE, MD .................................................................................................................................................. 06/20/00

GODZHOYAN, ARPINE, LOS ANGELES, CA ....................................................................................................................................... 06/20/00

GONZALEZ, WILFREDO, MIAMI, FL ..................................................................................................................................................... 06/20/00

GOODBODY, JOHN P, WEBSTER, NY ................................................................................................................................................. 06/20/00

HERAVI, BIJAN, LOS ANGELES, CA .................................................................................................................................................... 06/20/00

HERNDON, PATRICIA SUE, ENID, OK ................................................................................................................................................. 06/20/00

ILYAS, ZAHID, EDISON, NJ ................................................................................................................................................................... 06/20/00

KIDS CHARIOT, INC, COLORADO SPRNGS, CO ................................................................................................................................ 06/20/00